Elekta Sets New Benchmark for Cancer Treatment with Launch of Versa HD System

ATLANTA and STOCKHOLM, March 1 – During a live global event, Elekta announced the launch of Versa HD™, an advanced linear accelerator system designed to improve patient care and treat a broader spectrum of cancers. Featuring high precision beam shaping and tumor targeting, Versa HD also unveils new capabilities designed to maximize health care system resources and deliver highly sophisticated therapies without compromising treatment times.

Versa HD gives clinicians the flexibility to deliver conventional therapies to treat a wide range of tumors throughout the body, while also enabling treatment of highly complex cancers that require extreme targeting precision. As an integrated treatment system, Versa HD offers the versatility to address today’s growing cancer management challenges.

“The well-being of increasing numbers of cancer patients worldwide inspired us to create Versa HD,” says Elekta’s President and CEO, Tomas Puusepp. “We strived to incorporate technologies that would provide an immediate impact to patient health and quality of life. As the pioneers of many of today’s most advanced therapies, we are proud to introduce Versa HD as yet another market-leading innovation. Versa HD truly reflects the best thinking of Elekta’s technical experts and our clinical partners.”

Integrated with Elekta’s recently-launched Agility™ 160-leaf multileaf collimator (MLC), Versa HD provides highly conformal beam shaping – a critical requirement for maximizing the dose to the target while also preserving surrounding healthy tissues. Importantly, this high targeting accuracy is available over a large field-of-view, permitting delivery of high-definition (HD) beams to a wide spectrum of complex targets.

source: Elekta